Since its discovery in 2008, adropin has been shown to improve peripheral endothelial dysfunction, reduce insulin resistance, and increase glucose utilization in obesity and diabetes [1, 3, 19, 20], and clinical studies have found a significant association between altered plasma adropin and the risk of ischemic heart diseases [5, 8, 21, 22]. The gene discussed is ENHO; the disease is obesity due to melanocortin 4 receptor deficiency.